Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Get Rating) fell 4.6% during mid-day trading on Tuesday . The stock traded as low as $16.98 and last traded at $17.01. 15,130 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 1,523,321 shares. The stock had previously closed at $17.83.
Separately, Citigroup lifted their price objective on shares of Amylyx Pharmaceuticals from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, June 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $38.50.
The firm’s 50 day simple moving average is $10.58.
Amylyx Pharmaceuticals Company Profile (NASDAQ:AMLX)
Amylyx Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases.
See Also
- Get a free copy of the StockNews.com research report on Amylyx Pharmaceuticals (AMLX)
- ABM Industries, A Clean Play For Dirty Economic Times
- This Still Isn’t A Buyable Bottom For Stocks
- Should Silver Stocks Be A Part Of Your Portfolio?
- Dividend-Paying Midstream Oil Companies That Could Help You The Mitigate Market Volatility
- Two Defensive Stocks To Get Aggressive With
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
